A two-faced selectivity solution to target SMARCA2 for cancer therapy.
Where this comes from
- Record sourced from PubMed, PMID 36720862.
- Also identified by DOI 10.1038/s41467-023-36238-0 and PMC identifier 9889305.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Two new studies exploring PROTAC-mediated degradation of SMARCA2 for cancer therapy solve an apparently intractable selectivity challenge with SMARCA4 by utilising the requirement for a productive ternary complex between the protein, PROTAC and ligase complex.
Medical subject headings
- Neoplasms